Skylar Jeremias

Skylar Jeremias is the Managing Editor for The Center for Biosimilars and The American Journal of Managed Care (AJMC).


Patent Dance Insights: A Q&A on Reducing Legal Battles in the Biosimilar Landscape

August 18, 2024

In an interview, Ha Kung Wong, an intellectual property attorney, explained that the Biologics Price Competition and Innovation Act of 2009 provides a structured but optional "patent dance" for biosimilars, which helps streamline patent disputes, potentially reducing litigation and encouraging early settlements.

No Differences in Long-Term Drug Survival Between Biosimilar, Originator TNF Inhibitors

August 15, 2024

An analysis of subcutaneous biosimilar and originator tumor necrosis factor (TNF) inhibitors for rheumatic diseases found no significant differences in survival or discontinuation rates due to inefficacy or adverse events, with biosimilars showing lower overall discontinuation rates and higher retention rates.

AI and Biosimilars: Bridging Global Health Disparities and Enhancing Treatment Efficiency

August 10, 2024

Artificial intelligence (AI) technologies can support global health systems in integrating biosimilars into care models, reducing health care costs, enhancing treatment decision-making strategies, and narrowing the gap between high-income and low- and middle-income countries.

Manitoba Adopts Biosimilar Switching Policy

August 07, 2024

Manitoba’s new policy means that all 10 Canadian provinces now have an initiative to boost biosimilar adoption and savings by transitioning patients on reference agents to biosimilar options.

Eye on Pharma: Ustekinumab Updates; Ranibizumab Trial; Julie Reed PBM Piece

August 06, 2024

Several companies receive good news regarding their ustekinumab biosimilars; Lupin Limited completes a phase 3 trial for a ranibizumab candidate; Julie Reed, MS, executive director of the Biosimilars Forum weighs in on pharmacy benefit managers and biosimilar access.

Indian Providers Boast Interchangeability for Insulin Biosimilars Despite Debates in the US

August 05, 2024

The introduction of biosimilar insulins, particularly insulin glargine, is crucial for improving insulin accessibility and adherence among patients with diabetes in India, according to a study evaluating expert opinions from Indian doctors.

Biosimilars Policy Roundup for July 2024—Podcast Edition

August 04, 2024

On this episode of Not So Different, we review all the big biosimilar policy news from July, including discussions regarding biosimilar policies, in both the US and abroad, as well as 3 highly anticipated FDA approvals.